1-20 of 28
Caroline Robert
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract PO-009: Phase 3 KEYNOTE-630 study of adjuvant pembrolizumab in high-risk locally advanced cutaneous squamous cell carcinoma

Michael Schenker, Mikhail Klochikhin, Dmitry Kirtbaya, Laurent Mortier, Martin Gschnell, Caroline Robert, Nicolas Meyer, Lukas Flatz, Stephane Dalle, Marie Beylot-Barry, Thomas Eigentler, Rachel Kloss Silverman, Burak Gumuscu, Jianda Yuan, Aase Bratland
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (18_Supplement): PO-009.
https://doi.org/10.1158/1557-3265.AACRAHNS23-PO-009
Published: 15 September 2023
View article titled, Abstract PO-009: Phase 3 KEYNOTE-630 study of adjuvant pembrolizumab in high-risk locally advanced cutaneous squamous cell carcinoma
Journal Articles

Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1

Caroline Robert, Céleste Lebbé, Thierry Lesimple, Eija Lundström, Valérie Nicolas, Bruno Gavillet, Philippa Crompton, Barouyr Baroudjian, Emilie Routier, Ferdy J. Lejeune
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (5): 858–865.
https://doi.org/10.1158/1078-0432.CCR-22-2812
Published: 01 March 2023
View article titled, Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
Open the PDF for Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1 in another window
Includes: Supplementary data
Journal Articles

Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases

James S. Wilmott, Hussein Tawbi, Johnathan A. Engh, Nduka M. Amankulor, Brindha Shivalingam, Hiya Banerjee, Ismael A. Vergara, Hansol Lee, Peter A. Johansson, Peter M. Ferguson, Philippe Saiag, Caroline Robert, Jean-Jacques Grob, Lisa H. Butterfield, Richard A. Scolyer, John M. Kirkwood, Georgina V. Long, Michael A. Davies
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (3): 521–531.
https://doi.org/10.1158/1078-0432.CCR-22-2581
Published: 01 February 2023
View article titled, Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
Open the PDF for Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases in another window
Includes: Supplementary data
Journal Articles

Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell Carcinoma

Andrey A. Yurchenko, Oltin T. Pop, Meriem Ighilahriz, Ismael Padioleau, Fatemeh Rajabi, Hayley J. Sharpe, Nicolas Poulalhon, Brigitte Dreno, Amir Khammari, Marc Delord, Antonio Alberti, Nadem Soufir, Maxime Battistella, Samia Mourah, Fanny Bouquet, Ariel Savina, Andrej Besse, Max Mendez-Lopez, Florent Grange, Sandrine Monestier, Laurent Mortier, Nicolas Meyer, Caroline Dutriaux, Caroline Robert, Philippe Saiag, Florian Herms, Jerome Lambert, Frederic J. de Sauvage, Nicolas Dumaz, Lukas Flatz, Nicole Basset-Seguin, Sergey I. Nikolaev
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (7): 1422–1432.
https://doi.org/10.1158/1078-0432.CCR-21-3764
Published: 01 April 2022
View article titled, Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell Carcinoma
Open the PDF for Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma

Isabelle Girault, Julien Adam, Shensi Shen, Séverine Roy, Caroline Brard, Sara Faouzi, Emilie Routier, Jéremy Lupu, Sarah Warren, Kristina Sorg, SuFey Ong, Pascale Morel, Jean-Yves Scoazec, Stéphan Vagner, Caroline Robert
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (3): 518–525.
https://doi.org/10.1158/1078-0432.CCR-21-1229
Published: 01 February 2022
View article titled, A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma
Open the PDF for A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma in another window
Includes: Supplementary data
Journal Articles

Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules

Georgina V. Long, Caroline Robert, Marcus O. Butler, Felix Couture, Matteo S. Carlino, Steven O'Day, Victoria Atkinson, Jonathan S. Cebon, Michael P. Brown, Stéphane Dalle, Andrew G. Hill, Geoffrey T. Gibney, Steven McCune, Alexander M. Menzies, Cuizhen Niu, Nageatte Ibrahim, Blanca Homet Moreno, Adi Diab
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (19): 5280–5288.
https://doi.org/10.1158/1078-0432.CCR-21-0793
Published: 01 October 2021
View article titled, Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules
Open the PDF for Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules in another window
Includes: Supplementary data
Journal Articles

Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib

Jan C. Brase, Robert F.H. Walter, Alexander Savchenko, Daniel Gusenleitner, James Garrett, Tobias Schimming, Renata Varaljai, Deborah Castelletti, Ju Kim, Naveen Dakappagari, Ken Schultz, Caroline Robert, Georgina V. Long, Paul D. Nathan, Antoni Ribas, Keith T. Flaherty, Boguslawa Karaszewska, Jacob Schachter, Antje Sucker, Kurt W. Schmid, Lisa Zimmer, Elisabeth Livingstone, Eduard Gasal, Dirk Schadendorf, Alexander Roesch
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (16): 4500–4510.
https://doi.org/10.1158/1078-0432.CCR-20-3586
Published: 15 August 2021
View article titled, Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib
Open the PDF for Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib in another window
Includes: Supplementary data
Journal Articles

Interventional Radiology for Local Immunotherapy in Oncology

Lambros Tselikas, Stephane Champiat, Rahul A. Sheth, Steve Yevich, Samy Ammari, Frederic Deschamps, Siham Farhane, Charles Roux, Sandrine Susini, Severine Mouraud, Alexandre Delpla, Thibault Raoult, Caroline Robert, Christophe Massard, Fabrice Barlesi, Jean-Charles Soria, Aurélien Marabelle, Thierry de Baere
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (10): 2698–2705.
https://doi.org/10.1158/1078-0432.CCR-19-4073
Published: 15 May 2021
View article titled, Interventional Radiology for Local Immunotherapy in Oncology
Open the PDF for Interventional Radiology for Local Immunotherapy in Oncology in another window
Includes: Multimedia, Supplementary data
Journal Articles

Intratumoral Immunotherapy: From Trial Design to Clinical Practice

Stéphane Champiat, Lambros Tselikas, Siham Farhane, Thibault Raoult, Matthieu Texier, Emilie Lanoy, Christophe Massard, Caroline Robert, Samy Ammari, Thierry De Baère, Aurélien Marabelle
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (3): 665–679.
https://doi.org/10.1158/1078-0432.CCR-20-0473
Published: 01 February 2021
View article titled, Intratumoral Immunotherapy: From Trial Design to Clinical Practice
Open the PDF for Intratumoral Immunotherapy: From Trial Design to Clinical Practice in another window
Journal Articles

Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration—Melanoma Research Alliance Public Workshop

Kristen L. Mueller, Marc R. Theoret, Steven J. Lemery, Laleh Amiri-Kordestani, Charlotte E. Ariyan, Michael B. Atkins, Donald A. Berry, Christian U. Blank, Angela M. DeMichele, Patrick M. Forde, Nageatte Ibrahim, Patricia Keegan, Tara C. Mitchell, Rebecca A. Moss, Caroline Robert, Rajeshwari Sridhara, Janis M. Taube, Michael T. Tetzlaff, Jennifer A. Wargo, Keith T. Flaherty, Michael J. Kaplan, Suzanne L. Topalian, Ashley F. Ward, Marc S. Hurlbert
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (2): 394–401.
https://doi.org/10.1158/1078-0432.CCR-20-3285
Published: 19 January 2021
View article titled, Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration—Melanoma Research Alliance Public Workshop
Open the PDF for Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration—Melanoma Research Alliance Public Workshop in another window
Journal Articles

Abstract S02-01: Clinical characteristics and outcomes of coronavirus 2019 disease (COVID-19) in cancer patients treated with immune checkpoint inhibitors (ICI)

Aljosja Rogiers, Carlo Tondini, Joe M. Grimes, Megan H. Trager, Sharon Nahm, Leyre Zubiri, Neha Papneja, Arielle Elkrief, Jessica Borgers, April Rose, Johanna Mangana, Michael Erdmann, Ines Pires da Silva, Christian Posch, Axel Hauschild, Lisa Zimmer, Paola Queirolo, Caroline Robert, Karijn Suijkerbuijk, Paolo A. Ascierto, Paul Lorigan, Richard Carvajal, Osama E Rahma, Mario Mandala, Georgina V. Long
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (18_Supplement): S02-01.
https://doi.org/10.1158/1557-3265.COVID-19-S02-01
Published: 15 September 2020
View article titled, Abstract S02-01: Clinical characteristics and outcomes of coronavirus 2019 disease (COVID-19) in cancer patients treated with immune checkpoint inhibitors (ICI)
Journal Articles

Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era

Michele Maio, Omid Hamid, James Larkin, Alessia Covre, Maresa Altomonte, Luana Calabrò, Santosh A. Vardhana, Caroline Robert, Ramy Ibrahim, Andrea Anichini, Jedd D. Wolchok, Anna Maria Di Giacomo
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (16): 4201–4205.
https://doi.org/10.1158/1078-0432.CCR-20-1657
Published: 14 August 2020
View article titled, Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era
Open the PDF for Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era in another window
Journal Articles

Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAFV600-mutated Metastatic Melanoma

Yibing Yan, Matthew J. Wongchenko, Caroline Robert, James Larkin, Paolo A. Ascierto, Brigitte Dréno, Michele Maio, Claus Garbe, Paul B. Chapman, Jeffrey A. Sosman, Zhen Shi, Hartmut Koeppen, Jessie J. Hsu, Ilsung Chang, Ivor Caro, Isabelle Rooney, Grant A. McArthur, Antoni Ribas
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (11): 3239–3246.
https://doi.org/10.1158/1078-0432.CCR-18-0720
Published: 01 June 2019
View article titled, Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with <em>BRAF</em><sup>V600</sup>-mutated Metastatic Melanoma
Open the PDF for Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with <em>BRAF</em><sup>V600</sup>-mutated Metastatic Melanoma in another window
Includes: Supplementary data
Journal Articles

Long-Term Survival in Patients Responding to Anti–PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation

Marie-Léa Gauci, Emilie Lanoy, Stéphane Champiat, Caroline Caramella, Samy Ammari, Sandrine Aspeslagh, Andrea Varga, Capucine Baldini, Rastilav Bahleda, Anas Gazzah, Jean-Marie Michot, Sophie Postel-Vinay, Eric Angevin, Vincent Ribrag, Antoine Hollebecque, Jean-Charles Soria, Caroline Robert, Christophe Massard, Aurélien Marabelle
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (3): 946–956.
https://doi.org/10.1158/1078-0432.CCR-18-0793
Published: 01 February 2019
View article titled, Long-Term Survival in Patients Responding to Anti–PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation
Open the PDF for Long-Term Survival in Patients Responding to Anti–PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation in another window
Includes: Supplementary data
Journal Articles

Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

Richard W. Joseph, Jeroen Elassaiss-Schaap, Richard Kefford, Wen-Jen Hwu, Jedd D. Wolchok, Anthony M. Joshua, Antoni Ribas, F. Stephen Hodi, Omid Hamid, Caroline Robert, Adil Daud, Roxana Dronca, Peter Hersey, Jeffrey S. Weber, Amita Patnaik, Dinesh P. de Alwis, Andrea Perrone, Jin Zhang, S. Peter Kang, Scot Ebbinghaus, Keaven M. Anderson, Tara C. Gangadhar
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (23): 6098.
https://doi.org/10.1158/1078-0432.CCR-18-3340
Published: 03 December 2018
View article titled, Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
Open the PDF for Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab in another window
Journal Articles

Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

Richard W. Joseph, Jeroen Elassaiss-Schaap, Richard Kefford, Wen-Jen Hwu, Jedd D. Wolchok, Anthony M. Joshua, Antoni Ribas, F. Stephen Hodi, Omid Hamid, Caroline Robert, Adil Daud, Roxana Dronca, Peter Hersey, Jeffrey S. Weber, Amita Patnaik, Dinesh P. de Alwis, Andrea Perrone, Jin Zhang, S. Peter Kang, Scot Ebbinghaus, Keaven M. Anderson, Tara C. Gangadhar
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (20): 4960–4967.
https://doi.org/10.1158/1078-0432.CCR-17-2386
Published: 15 October 2018
View article titled, Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
Open the PDF for Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab in another window
Includes: Supplementary data
Journal Articles

Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma

Jean-Pierre Delord, Caroline Robert, Marta Nyakas, Grant A. McArthur, Ragini Kudchakar, Amit Mahipal, Yasuhide Yamada, Ryan Sullivan, Ana Arance, Richard F. Kefford, Matteo S. Carlino, Manuel Hidalgo, Carlos Gomez-Roca, Daniela Michel, Abdelkader Seroutou, Vassilios Aslanis, Giordano Caponigro, Darrin D. Stuart, Laure Moutouh-de Parseval, Tim Demuth, Reinhard Dummer
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (18): 5339–5348.
https://doi.org/10.1158/1078-0432.CCR-16-2923
Published: 15 September 2017
View article titled, Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic <em>BRAF</em>-Mutant Melanoma
Open the PDF for Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic <em>BRAF</em>-Mutant Melanoma in another window
Includes: Supplementary data
Journal Articles

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody

Neil H. Segal, Theodore F. Logan, F. Stephen Hodi, David McDermott, Ignacio Melero, Omid Hamid, Henrik Schmidt, Caroline Robert, Vanna Chiarion-Sileni, Paolo A. Ascierto, Michele Maio, Walter J. Urba, Tara C. Gangadhar, Satyendra Suryawanshi, Jaclyn Neely, Maria Jure-Kunkel, Suba Krishnan, Holbrook Kohrt, Mario Sznol, Ronald Levy
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (8): 1929–1936.
https://doi.org/10.1158/1078-0432.CCR-16-1272
Published: 13 April 2017
View article titled, Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
Open the PDF for Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody in another window
Includes: Supplementary data
Journal Articles

Molecular Pathways: The eIF4F Translation Initiation Complex—New Opportunities for Cancer Treatment

Hélène Malka-Mahieu, Michelle Newman, Laurent Désaubry, Caroline Robert, Stéphan Vagner
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (1): 21–25.
https://doi.org/10.1158/1078-0432.CCR-14-2362
Published: 02 January 2017
View article titled, Molecular Pathways: The eIF4F Translation Initiation Complex—New Opportunities for Cancer Treatment
Open the PDF for Molecular Pathways: The eIF4F Translation Initiation Complex—New Opportunities for Cancer Treatment in another window
Includes: Supplementary data
Journal Articles

Abstract A23: eIF4F is a key and targetable convergence nexus of multiple mechanisms of resistance to anti-BRAF and anti-MEK cancer therapies

Lise Boussemart, Helene Malka-Mahieu, Isabelle Girault, Delphine Allard, Oskar Hemmingson, Nyam Kamsu-Kom, Sandrine Agoussi, Alexander Eggermont, Laurent Desaubry, Caroline Robert, Stephan Vagner
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (4_Supplement): A23.
https://doi.org/10.1158/1557-3265.PMS14-A23
Published: 13 February 2015
View article titled, Abstract A23: eIF4F is a key and targetable convergence nexus of multiple mechanisms of resistance to anti-BRAF and anti-MEK cancer therapies